FIELD: medicine.
SUBSTANCE: present invention refers to medicine, namely to therapy and pulmonology, and concerns treating or relieving idiopathic pulmonary fibrosis. To this end, a composition, including 6-ECDCA or analogues thereof is administered.
EFFECT: reducing the amount of collagen I and CXCL12 produced by fibrocytes in the lungs or at the point of lung injury.
7 cl, 5 ex, 22 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DEUTERATED DERIVATIVE OF CHENODEOXYCHOLIC ACID AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND | 2016 |
|
RU2712033C2 |
| COMBINED THERAPY WITH APPLICATION OF CENICRIVIROC FOR FIBROSIS TREATMENT | 2015 |
|
RU2723559C2 |
| METHODS OF USING AGONISTS FXR | 2017 |
|
RU2737324C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATHOEPATITIS | 2021 |
|
RU2803733C1 |
| METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
| REDUCTION OF ARGINASE LEVELS/ACTIVITY | 2007 |
|
RU2469742C2 |
| PYRAZOLE DERIVATIVES AND THEIR USE | 2020 |
|
RU2805207C1 |
| METHODS AND COMPOSITIONS RELATED TO EMULSIONS CONTAINING FISH OIL AND/OR OMEGA-3 FATTY ACIDS | 2018 |
|
RU2783166C2 |
| NEW EP4 AGONIST | 2011 |
|
RU2564414C2 |
| USE OF GLYCYRRHETINIC ACID, GLYCYRRHIZIC ACID AND RELATED COMPOUNDS FOR PREVENTING AND/OR TREATING PULMONARY FIBROSIS | 2010 |
|
RU2575825C2 |
